Abstract:The essential trace element iron is a key component of hemoglobin, playing a role in erythropoiesis and oxygen transport. In addition, iron plays a key role in several enzymatic and metabolic processes. Iron deficiency causes anemia, whereas iron overload causes organ-related diseases such as heart failure, liver cirrhosis, and diabetes mellitus. Therefore, maintaining iron homeostasis is essential for the survival of nearly all living organisms. Iron overload-related cardiomyopathy is a secondary form of heart disease resulting from iron accumulation in the myocardium and is the leading cause of morbidity in hereditary hemochromatosis, thalassemia major, and other conditions associated with secondary iron overload. A growing body of epidemiological and molecular evidence supports the notion that iron overload is pathogenic and that iron chelation therapy can be clinically beneficial in treating many forms of heart disease. However, the precise mechanisms by which iron overload leads to heart disease are poorly understood. In recent years, significant progress has been made toward understanding the regulatory mechanisms that underlie iron overload in many diseases. In particular, ferroptosis, a newly identified iron-dependent form of cell death, has drawn considerable attention. Ferroptosis has morphological, biochemical, and genetic features that are distinct from other forms of cell death such as apoptosis, necrosis, and autophagy, and mounting evidence suggests that ferroptosis participates in the initiation and progression of many diseases and conditions, including tumorigenesis, ischemia/reperfusion injury, kidney failure, and diseases affecting the nervous system and the hematological system. Although the death of terminally differentiated cardiomyocytes is a crucial pathogenic factor in the development of cardiomyopathy, the underlying mechanism remains unknown. Recently, we reported that inhibiting ferroptosis in mice can protect against both chemotherapy-induced cardiomyopathy and ischemia/reperfusion-induced cardiomyopathy. With respect to the underlying mechanism, we found that excess accumulation of free iron in the mitochondria of cardiomyocytes causes membrane lipid peroxidation, providing new insights into the pathogenic mechanisms that underlie iron overload-associated cardiomyopathy. In this review, we briefly introduce the molecular mechanisms that regulate cardiac iron homeostasis. In addition, we provide an overview of studies regarding the role that iron overload-associated cardiomyopathy and ferroptosis play in the pathogenesis and progression of heart disease. Finally, we discuss the role of targeting ferroptosis as a promising new therapeutic strategy for myocardial chemotherapeutic and ischemia/reperfusion injury.

A Novel Circpik3c2a/mir‐31‐5p/tfrc Axis Drives Ferroptosis and Accelerates Myocardial Injury

Cardiac Extracellular Vesicles Aggravate Cardiomyocyte Ferroptosis in Myocardial Ischemia-Reperfusion Injury Via Mir-155-5p-nfe2l2 Signaling

Multifaceted Role of Ferroptosis in Cardiovascular Disease

Ferroptosis as a target for protection against cardiomyopathy

Noncoding RNAs regulating ferroptosis in cardiovascular diseases: novel roles and therapeutic strategies

MiRNA Regulates Ferroptosis in Cardiovascular and Cerebrovascular Diseases

Ferroptosis as a novel therapeutic target for cardiovascular disease

circSnx12 Is Involved in Ferroptosis During Heart Failure by Targeting miR-224-5p

Role of Iron Overload and Ferroptosis in Heart Disease

Platelet Internalization Mediates Ferroptosis in Myocardial Infarction

Circ_005077 accelerates myocardial lipotoxicity induced by high-fat diet via CyPA/p47PHOX mediated ferroptosis

CircRNA1615 Inhibits Ferroptosis Via Modulation of Autophagy by the Mirna152-3P/lrp6 Axis in Cardiomyocytes of Myocardial Infarction

Loss of Cardiac Ferritin H Facilitates Cardiomyopathy via Slc7a11-Mediated Ferroptosis

miR-135b-3p Promotes Cardiomyocyte Ferroptosis by Targeting GPX4 and Aggravates Myocardial Ischemia/Reperfusion Injury

Inhibition of miR-214-3p attenuates ferroptosis in myocardial infarction via regulating ME2

Circular RNA FEACR inhibits ferroptosis and alleviates myocardial ischemia/reperfusion injury by interacting with NAMPT

Ferrostatin-1 suppresses cardiomyocyte ferroptosis after myocardial infarction by activating Nrf2 signaling

Ferroptosis is a Potential Novel Diagnostic and Therapeutic Target for Patients with Cardiomyopathy

A Novel Insight Into the Fate of Cardiomyocytes in Ischemia-Reperfusion Injury: From Iron Metabolism to Ferroptosis

Ferroptosis: a new strategy for cardiovascular disease

Targeting ferroptosis and ferritinophagy: new targets for cardiovascular diseases